| Schedule of Computation of Net Loss Per Common Share |
The following table sets forth the computation of net loss per common share (in thousands except share and per share amounts): | | | Six Months Ended
June 30 | | | | 2026 | | 2025 | | Net loss per share | | | | | | | | | | Numerator | | | | | | | | | | Net loss | | $ | (9,610 | ) | | $ | (5,645 | ) | | Numerator for basic and diluted net loss per share | | $ | (9,610 | ) | | $ | (5,645 | ) | | | | Six Months Ended
June 30 | | | | 2026 | | 2025 | | Denominator | | | | | | | | | | Weighted average common shares outstanding | | | 10,684,069 | | | | 10,613,166 | | | Denominator for basic and diluted loss per share | | | 10,684,069 | | | | 10,613,166 | | | | | | | | | | | | | Net loss per share | | | | | | | | | | Basic and diluted | | $ | (0.90 | ) | | $ | (0.53 | ) |
|
The following table sets forth the computation of net loss per common share (in thousands except share and per share amounts): | | | Year ended December 31 | | | | 2025 | | 2024 | | Net loss per share | | | | | | | | | | Numerator | | | | | | | | | | Net loss | | $ | (12,199 | ) | | $ | (10,065 | ) | | Numerator for basic and diluted net loss per share | | $ | (12,199 | ) | | $ | (10,065 | ) | | | | | | | | | | | | Denominator | | | | | | | | | | Weighted average common shares outstanding | | | 10,638,595 | | | | 10,575,252 | | | Denominator for basic and diluted loss per share | | | 10,638,595 | | | | 10,575,252 | | | | | | | | | | | | | Net loss per share | | | | | | | | | | Basic and diluted | | $ | (1.15 | ) | | $ | (0.95 | ) |
|
| Schedule of Computation of Diluted Net Loss Per Share |
The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: | | | Six Months Ended
June 30, | | | | 2026 | | 2025 | | Series Seed-1 (as converted to common stock) | | 1,536,006 | | 1,536,006 | | Series Seed-2 (as converted to common stock) | | 1,099,412 | | 1,099,412 | | Series A-1 (as converted to common stock) | | 1,059,058 | | 1,059,058 | | Series A (as converted to common stock) | | 2,652,734 | | 2,652,734 | | Series SA-2 (as converted to common stock) | | 1,745,625 | | 1,745,625 | | Series A-2 (as converted to common stock) | | 3,184,572 | | 3,184,572 | | Series X (as converted to common stock) | | 779,240 | | — | | Stock options to purchase common stock | | 3,256,084 | | 3,362,773 | | Unvested restricted common stock | | 809,464 | | — | | | | 16,122,195 | | 14,640,180 |
|
The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: | | | Year ended December 31, | | | | 2025 | | 2024 | | Series Seed-1 (as converted to common stock) | | 1,536,006 | | 1,536,006 | | Series Seed-2 (as converted to common stock) | | 1,099,412 | | 1,099,412 | | Series A-1 (as converted to common stock) | | 1,059,058 | | 1,059,058 | | Series A (as converted to common stock) | | 2,652,734 | | 2,652,734 | | Series SA-2 (as converted to common stock) | | 1,745,625 | | 1,745,625 | | Series A-2 (as converted to common stock) | | 3,184,572 | | 1,773,460 | | Series X (as converted to common stock) | | 769,114 | | — | | Stock options to purchase common stock | | 3,307,849 | | 1,617,266 | | Unvested restricted common stock | | 329,104 | | — | | | | 15,683,474 | | 11,483,561 |
|